SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy is trending as investors monitor its transition to more streamlined NRC licensing processes and potential expansion into data center power solutions, with the community actively debating whether current stock weakness offers a long-term entry point ahead of future milestone events. Discussions are heavily focused on the company's competitive position within the nuclear energy sector, its reliance on government project funding, and the impact of institutional activity on price volatility.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is seeing intense community engagement as investors weigh long-term nuclear demand against the stock's recent valuation premium and quarterly results. While sentiment remains divided over short-term price action, there is strong, consistent support for the sector's role in powering AI infrastructure and national energy security.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus Energy Corp is gaining significant attention as investors react to a major government funding award aimed at accelerating domestic uranium enrichment capabilities. The community is actively discussing the stock's pivotal role in the nuclear fuel supply chain, with many highlighting its position as a primary beneficiary of the growing demand for HALEU and the broader nuclear renaissance.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is building a stake in the company ahead of a potential takeover bid. While the community is actively debating the feasibility and financial logistics of such an acquisition, sentiment remains divided between those expecting a strategic expansion and others skeptical of the deal's structure and viability.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWX Technologies is capturing investor interest as a vital player in the nuclear energy sector, fueled by its role in supplying reactor components for both government defense projects and emerging small modular reactor (SMR) initiatives. The community is actively discussing the stock's long-term potential as a 'picks and shovels' play on nuclear energy infrastructure, particularly as demand for power in AI data centers continues to surge.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano is trending as the community highlights the project's integration of real-world revenue from its food business to drive token buybacks and passive income mechanics. Investors are actively discussing the project's long-term potential as an RWA memecoin on the Cardano blockchain, frequently referencing its community-led initiatives and upcoming events.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is capturing significant community attention as developers ramp up testing for the new LitVM rollup, driving discussion around its potential to evolve into a broader DeFi and smart contract ecosystem. Despite ongoing debate about price performance and market dominance, traders remain focused on its historical long-term setup and the impact of increasing institutional infrastructure, such as ETP integrations and treasury accumulation.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing active community debate as investors weigh potential market recovery against long-term skepticism, while high-volume traders continue to monitor supply levels and ecosystem developments. Sentiment remains polarized between those holding for a long-term supply shock and others who view the asset as a speculative trap in the current cycle.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is experiencing heightened investor activity driven by speculation over regulatory clarity and a broader market rebound, with community sentiment deeply divided between long-term holders anticipating a significant bull run and skeptics labeling the asset a stalled project. Discussion is currently focused on potential legislative catalysts, whale accumulation patterns, and the project's ability to maintain pace with the wider crypto recovery.

Alchemy Pay

Alchemy Pay is drawing significant attention from the community as investors debate the potential of its upcoming Layer 1 blockchain and stablecoin integration, with many split between bullish long-term adoption and frustration over supply inflation. The discourse remains highly polarized, featuring vocal competition with other payment-focused tokens while traders closely monitor its price action against broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ImmunityBio said it removed the referenced podcast from its website and requested removal from external platforms.</li><li>Enhanced compliance measures will include stricter promotional review protocols and mandatory executive-level training.</li><li>ANKTIVA, ImmunityBio’s interleukin-15-based immunotherapy, remains central to the company’s oncology strategy.</li></ul>ImmunityBio Inc. (IBRX) stated on Monday that it has responded to regulatory concerns raised by the U.S. Food and Drug Administration, outlining corrective steps related to promotional content for its cancer therapy as the company seeks to reinforce compliance standards.The company said it submitted a detailed reply to the FDA’s Office of Prescription Drug Promotion following a March 13 communication on marketing materials, including a podcast and a television advertisement.&nbsp;<h2 class="st-heading-2">FDA Inquiry And ImmunityBio’s Response</h2>ImmunityBio clarified that the advertisement in question was never released to the public and addressed issues tied to statements made in the podcast.&nbsp;In response, ImmunityBio removed the referenced podcast from its website and requested its deletion from external platforms hosting the content.&nbsp;<blockquote>“We are dedicated to maintaining a clear distinction between our investigational pipeline aspirations and the promoted indications for our approved therapies.”-Richard Adcock, President and CEO, ImmunityBio</blockquote>&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio stock</a> traded over 3% higher in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Compliance Measures</h2>The Culver City-based firm said it is introducing tighter oversight procedures, including enhanced review protocols for marketing materials, mandatory executive-level compliance training, and the addition of external regulatory advisors to evaluate future communications. These measures are intended to ensure that promotional messaging aligns with FDA standards for accuracy and balance.The podcast in question featured founder Patrick Soon-Shiong, who was discussing long-term scientific ambitions.The company emphasized its commitment to providing clear and compliant information about ANKTIVA, an immunotherapy designed to stimulate key immune cells that target cancer. The treatment builds on the biology of interleukin-15 to enhance the immune response, forming part of ImmunityBio’s broader oncology strategy.IBRX stock has gained over 268% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slno-stock-soars-over-39-what-s-fueling-the-rally/cZJ4SjzRIoU">SLNO Stock Soars Over 39% — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight

ImmunityBio company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.

Equity

The company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.


<ul class="summary-bullets"><li>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments.</li><li>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030.</li><li>In February, Day One reported strong momentum for its lead therapy, OJEMDA.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) announced on Friday that it has entered into an acquisition agreement with Servier, an independent pharmaceutical company managed by a foundation.The deal, valued at roughly $2.5 billion, will see Servier purchase Day One shares for $21.50 each in cash, marking a 64% premium over DAWN’s closing price on Thursday.<h2 class="st-heading-2">Expansion In Oncology</h2>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments and broaden its cancer pipeline for both adults and children facing high unmet medical needs.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One Biopharmaceuticals stock</a> surged over 65% on Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<h2 class="st-heading-2">Pipeline Growth And 2030 Ambition</h2>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030. The addition of Day One’s programs, ranging from early-stage research to phase 3 trials, enhances Servier’s capacity to deliver solutions for cancers with critical unmet needs.<blockquote>“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma.”-Jeremy Bender, CEO, Day One</blockquote>In February, Day One&nbsp;reported strong momentum for its lead therapy, OJEMDA, highlighting prescription volumes for OJEMDA reached 1,394 in the fourth quarter of 2025, with total prescriptions for the year at 4,635, marking a 181% year-on-year (YOY) growth.&nbsp;The company said updated three-year results from the Phase 2 FIREFLY-1 trial demonstrated durable responses and long-term safety of OJEMDA in relapsed or refractory pediatric low-grade glioma (pLGG). Enrollment for the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in frontline pLGG remains on schedule, with full enrollment expected in the first half of 2026.DAWN stock traded over 132% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-in-spotlight-as-company-strengthens-us-nuclear-fuel-supply-chain-with-new-deal/cZdLbbRRIEr">ASPI Stock In Spotlight As Company Strengthens US Nuclear Fuel Supply Chain With New Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Day One Biopharmaceuticals logo is displayed on the screen of a tablet.

Why Did DAWN Skyrocket Over 65% Pre-Market Today? 

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.

<ul class="summary-bullets"><li>The company reported Q4 revenue of $92.02 million with an earnings per share (EPS) of $0.15.</li><li>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions.</li><li>The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.</li></ul>Liquidia Corp. (LQDA) on Thursday released its financial results for the fourth quarter (Q4), highlighting strong early traction in the commercial rollout of its respiratory drug, YUTREPIA.&nbsp;The company reported Q4 revenue of $92.02 million&nbsp;with an earnings per share (EPS) of $0.15. While revenue surpassed the analysts’ consensus estimate of $83.70 million, EPS came in below the $0.19 estimate, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">YUTREPIA Launch Drives Commercial Momentum</h2>The North Carolina-based company reported significant prescription growth for YUTREPIA since its U.S. launch in June 2025, with thousands of patients now receiving therapy. The drug’s early performance has become a key contributor to Liquidia’s improving financial outlook and operational momentum.Product revenue from YUTREPIA reached approximately $148.3 million in 2025,&nbsp;including about $90.1 million generated during the fourth quarter alone.<blockquote>“We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases.”-Roger Jeffs, CEO, Liquidia&nbsp;</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/LQDA">Liquidia’s stock</a> traded over 6% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ in 24 hours.&nbsp;<h2 class="st-heading-2">What’s Next?&nbsp;</h2>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions, with over 2,900 patients already starting treatment. The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.Jeffs said the company plans to increase the number of doctors prescribing the treatment, expand the sales team, add more clinical data for YUTREPIA through several new studies, and move L606 into key late-stage trials, all using funds generated from business operations.LQDA stock has gained over 121% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meta-lacks-deep-pool-of-cloud-demand-unlike-google-and-amazon-says-arete/cZdQYbhRI3T">Meta Lacks The 'Deep Pool' Of Cloud Demand, Unlike Google And Amazon, Says Arete</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Liquidia Corporation logo is seen displayed on a smartphone screen.

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth 

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Current Price	$84.97
Prev Close	$84.78
Open	$84.85
Dividend Yield	N/A
50-Day Moving Average	$83.73
Beta	N/A
Avg. Volume	7,000.11
PE Ratio	N/A

52-Week High	$88.11
52-Week Low	$53.12
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

BBP
ETFis Series Trust I - Virtus LifeSci Biotech Products ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BBP News

BBPETFis Series Trust I - Virtus LifeSci Biotech Products ETF